Trametinib (Megenin) is suitable for use and dose adjustment in patients with liver and kidney dysfunction

Trametinib is a highly selective MEK1/2 inhibitor that is often used in combination with dabrafenib to treat BRAF V600 mutant melanoma, lung cancer and other malignant tumors. This drug blocks the proliferation and survival of tumor cells by inhibiting the MAPK signaling pathway. In clinical use, since the liver and kidneys are important organs for drug metabolism and excretion, the safety and dose adjustment of trametinib are particularly critical in patients with liver and kidney dysfunction, and individualized management needs to be carried out according to the patient's specific metabolic ability.

From a pharmacokinetic perspective, trametinib is mainly excreted through liver metabolism and bile, with a lower proportion of renal excretion. Therefore, in patients with mild to moderate renal impairment, drug clearance does not change significantly and dose adjustment is generally not necessary. However, in patients with severe renal impairment (eGFR <30 mL/min), drug metabolism may be delayed, and plasma drug concentrations and adverse reactions should be closely monitored, and dosage reduction or dosing interval extension should be considered if necessary. For patients undergoing dialysis, due to the high protein binding rate and large distribution volume of trametinib, the dialysis clearance effect is limited, so it needs to be used with caution under strict monitoring.

The metabolic effects of trametinib are more significant in patients with hepatic insufficiency. Studies have shown that patients with mild hepatic impairment (Child-Pugh A) can maintain the regular dose (2 mg once daily); however, for patients with moderate or severe hepatic impairment (Child-Pugh B or C), plasma drug exposure may be significantly increased, thereby increasing the risk of adverse reactions such as rash, diarrhea, elevated liver enzymes, and abnormal cardiac function. Therefore, it is recommended to reduce the starting dose by half, i.e. 1 mg once daily, and to closely monitor liver function indicators and cardiac ejection fraction in the early stages of treatment. If the patient tolerates it well and the efficacy is insufficient, it can be gradually restored to the regular dose under the guidance of a doctor.
Generally speaking, trametinib is not a banned drug in patients with liver and kidney dysfunction, but the principle of "individualized evaluation and dynamic monitoring" must be followed. For patients with mild functional impairment, the standard medication regimen can be maintained; for moderately severe patients, the dose needs to be reduced and liver enzymes, renal function and cardiac status should be monitored regularly. In addition, concurrent use with strong CYP3A4 inhibitors or inducers should be avoided to prevent drug interactions leading to fluctuations in plasma concentrations. Reasonable dose adjustment and strict monitoring and management can not only reduce the risk of toxicity, but also ensure that trametinib can achieve the best therapeutic effect in special populations.
Reference: https://www.drugs.com/